Weekly Stock Comment: Ryman Healthcare


Ryman Healthcare is New Zealand’s pre-eminent listed retirement and aged care provider, providing services to over 9,000 residents. RYM’s integrated facilities, from independent apartments through to serviced units, resthome and hospital beds, cater for the changing needs of occupants as they age.

RYM has a strong focus on providing a continuum of care to residents with a circa 60:40 split between living units and aged-care beds. RYM’s business model provides the advantage of very strong cash flows, which is sufficient to support ongoing development. The company enjoys above average margins supported by a strong management team, operational synergies, solid pricing power, increased brand recognition and stable earnings and cash flows from a large and mature portfolio of villages.

The number of over 75’s is set to grow sharply in the next two decades, doubling to over 500,000. RYM is well-positioned to benefit from this accelerated growth in demand for retirement and aged care facilities and services, especially given its in-house design/development capability. Australia faces similar demographic challenges to New Zealand, which bodes well for RYM’s continued expansion into Australia.

A key driver of growth over the coming years will be Australia where RYM is aiming to have five villages operating by 2020. Australia is particularly promising as we believe RYM has a significant advantage over its competitors due to its continuum of care model. Most villages in Australia are currently either standalone retirement or aged care villages, and it can be disrupting for residents to move between villages. Sales at RYM’s first Melbourne village (Weary Dunlop) were the fastest the company has ever experienced and development margins will be higher than first anticipated (18% vs 15%). RYM has also received higher accommodation bonds for its aged care beds than its Australian peers, which will help fund future development.

In our view, RYM has the most attractive retirement/aged care portfolio in New Zealand in terms of locations and mix of assets within villages while the expansion into Australia is promising. Over the coming years, RYM will look to build three villages a year, one in Auckland, one elsewhere in New Zealand, and one in Australia. Rising property prices have been a major tailwind for the sector, with operators benefitting from resale gains. However, we expect a softening property market to dent sector sentiment and provide an earnings headwind. RYM remains the best positioned ahead of this in our view, with a high quality portfolio, proven track record and more defensive continuum of care model.

Risks to RYM include: 1) falling property prices, 2) reputational damage, 3) increased competition.

Read more Weekly Stock Comments:

Ryman Healthcare

Want our Insights in your Inbox? Subscribe to our fortnightly Market Insights email newsletter here.

Disclaimer: This publication by Craigs Investment Partners Limited is for New Zealand residents. It may not be reproduced or further distributed or published without the express prior approval of Craigs Investment Partners Limited. This publication is not intended for distribution to any person outside New Zealand except in accordance with all the legal requirements of the relevant jurisdiction. While this publication is based on information from sources which Craigs Investment Partners Limited considers reliable, its accuracy and completeness cannot be guaranteed. Craigs Investment Partners Limited, its partners and employees, do not accept liability for the results of any actions taken or not taken upon the basis of information in this publication, or for any negligent mis-statements, errors or omissions. Some information included in this publication is of an historical nature and may have been superseded. Historical performance does not guarantee future performance. Those acting upon information and recommendations do so entirely at their own risk. Craigs Investment Partners Limited and/or its partners and employees may, from time to time, have a financial interest in respect of some or all of the matters discussed. The research analyst or analysts responsible for the content of this publication certify that: (1) the views expressed and attributed to the research analyst or analysts in the publication accurately reflect their personal opinion(s) about the subject, securities and issuers and/or other subject matter as appropriate; and (2) no part of his or her compensation was, is or will be, directly or indirectly related to the specific recommendations or views contained in this publication. Craigs Investment Partners Limited did not take into account the investment objectives, financial situation or particular needs of any particular person in the preparation of this publication. Accordingly, before making any investment decision Craigs Investment Partners Limited recommends that you seek professional assistance from an investment adviser.

This is general information only. For personalised investment advice please contact an Investment Adviser or phone 0800 272 442.

Copyright © Craigs Investment Partners Limited 2017. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, without the prior written permission of Craigs Investment Partners Limited.